Entasis Therapeutics Holdings Inc. (ETTX) Stock Surges Following Promising Topline Results from ATTACK Clinical Trial

Entasis Therapeutics Holdings Inc. (ETTX) stock prices were down by 1.27% as of the market closing on October 18th, 2021. This brought the price per share down to USD$3.11. Subsequent premarket fluctuation saw the stock surge by 24.12%, bringing it up to USD$3.86.

ATTACK Trial Results

October 19th, 2021 saw ETTX stock report positive topline data from its ATTACK clinical trial. The global Phase 3 registration trial was designed to evaluate the safety and efficacy of SUL-DUR versus colistin in patients exhibiting infections resulting from Acinetobacter baumannii. The treatment achieved its primary endpoint with carbapenem-resistant Acinetobactor infections, evidenced by having demonstrated statistical superiority over colistin. The treatment also trumped colistin in mortality analyses in CRABC m-MITT and all study populations that were a part of the topline results. A statistically significant difference in clinical response was also observed at Test of Cure, in favor of SUL-DUR over colistin. The treatment also achieved its primary safety objective of achieving a statistically significant reduction in nephrotoxicity.

Landmark Clinical Study

ETTX stock’s ATTACK clinical trial was the first to successfully evaluate an investigational agent designed to target a specific drug-resistant Gram-negative pathogen. Accordingly, SUL-DUR is the first investigational drug that exhibited efficacy in a 28-day all-cause mortality trial that was focused on carbapenem-resistant Acinetobacter, which is an Urgent threat as defined and designated by the Center for Disease Control. The company is keen to collaborate with regulatory agencies in preparation for its first regulatory submission, which it expects halfway through 2022 year.

Scope of ETTX Stock’s SUL-DUR

There has been a dire need for physicians and patients to have access to new agents for drug-resistant bacteria. Acinetobacter infections have proven to be some of the most challenging to treat, consuming substantial healthcare resources while resulting in significant pain and suffering in patients vulnerable to the disease. Backed by positive safety and efficacy results, and promising clinical cure rates, the ATTACK trial was highly successful. Following pending approval, SUL-DUR has the potential to address the urgent need for alternative treatment options for patients with life-threatening infections caused by Acinetobacter species, including multidrug-resistant strains.

Future Outlook for ETTX Stock

ETTX stock is pushing for the accelerated development and commercialization of its proprietary SUL-DUR treatment. The company is poised to capitalize on the massively expanded scope of opportunities this development would bring. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value over the long term.